SCOTTSDALE, Ariz., April 16, 2019 /PRNewswire/ -- HonorHealth Research Institute announced that the first patients have beenenrolled in the SynIVUS-DAPT Study, a clinical study designed to test outcomes of decreasing the amount of time patients, with a high risk of bleeding, take antiplatelet medications after receiving a drug-eluting coronary stent.
All five HonorHealth hospitals in the greater Phoenix area are participating in the study. Two other hospital systems also are participating:
Individuals in this study have developed a blockage in one or more arteries in their heart which may require a drug-coated stent to open the blockage(s). The study also uses an imaging procedure called IVUS (intravascular ultrasound) at the time of the stent placement. The IVUS procedure looks at the placement of the stent to make sure it's fully opened and against the artery wall.
Individuals considered at high risk for bleeding include those who:
For more information, patients should call:
HonorHealth is a non-profit, local community healthcare system serving an area of 1.6 million people in the greater Phoenix area. The network encompasses five acute-care hospitals, an extensive medical group, outpatient surgery centers, a cancer care network, clinical research, medical education, a foundation and community services. HonorHealth has approximately 11,500 employees, 3,700 affiliated physicians and 3,100 volunteers.
HonorHealth was formed by a merger between Scottsdale Healthcare and John C. Lincoln Health Network. HonorHealth's mission is to improve the health and well-being of those we serve. Learn more at HonorHealth.com.
View original content:http://www.prnewswire.com/news-releases/honorhealth-research-institute-launches-study-to-research-benefit-to-patients-at-high-risk-of-bleeding-after-coronary-stent-implantation-300833164.html
Subscribe to our Free Newsletters!